Mycosis fungoides secondary prevention

Jump to navigation Jump to search

Mycosis fungoides Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Mycosis Fungoides from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

X-Ray

CT Scan

MRI

Echocardiography and Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Mycosis fungoides secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Mycosis fungoides secondary prevention

All Images
X-rays
Echo and Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Mycosis fungoides secondary prevention

CDC on Mycosis fungoides secondary prevention

Mycosis fungoides secondary prevention in the news

Blogs on Mycosis fungoides secondary prevention

Directions to Hospitals Treating Mycosis fungoides

Risk calculators and risk factors for Mycosis fungoides secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Sogand Goudarzi, MD [2]

Overview

There are no established measures for the secondary prevention of mycosis fungoides.

Secondary Prevention

  • There are no established measures for the secondary prevention of mycosis fungoides.
  • Effective measures for the secondary prevention of mycosis fungoides include:[1][2]
    • Effective measures for the secondary prevention of mycosis fungoides is follow up patients with active or progressive disease, every 4–6 weeks.
    • Phototherapy (PUVA and involves oral 8-methoxypsoralen) is the preservation in the early stage.

References

  1. Santos JL (June 1974). "[Projection of the Brazilian population: 1970-2000]". Rev Saude Publica (in Portuguese). Suppl: 91–102. PMID 4438970.
  2. Willemze, R; Hodak, E; Zinzani, P L; Specht, L; Ladetto, M (2018). "Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†". Annals of Oncology. 29 (Supplement_4): iv30–iv40. doi:10.1093/annonc/mdy133. ISSN 0923-7534.


Template:WikiDoc Sources